Moderna and Merck Cancer Vaccine Cuts Melanoma Spread and Recurrence in Major Phase-3 Trial science

Moderna and Merck Cancer Vaccine Cuts Melanoma Spread and Recurrence in Major Phase-3 Trial

A personalized cancer vaccine from Moderna and Merck has cleared its biggest clinical test yet. The experimental mRNA therapy, combined with Keytruda, significantly reduced melanoma recurrence and spread in a large Phase 3 trial. Doctors would use the treatment after surgery in patients whose melanoma has been removed but still carries a high risk of […]

Sven Kramer September 1, 2026
Read More →